.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,677,322

« Back to Dashboard

Claims for Patent: 6,677,322

Title: Use of mometasone furoate for treating airway passage and lung diseases
Abstract:The administration of aerosolize particles of mometasone furoate in the form of dry powders, solutions, or aqueous suspension for treating corticosteroid-responsive diseases of the surfaces of upper and/or lower airway passages and/or lungs, e.g., allergic rhinitis and asthma is disclosed.
Inventor(s): Sequeira; Joel A. (Scotch Plains, NJ), Cuss; Francis M. (Basking Ridge, NJ), Nolop; Keith B. (Millburn, NJ), Chaudry; Imtiaz A. (North Caldwell, NJ), Nagabhushan; Nagamani (Parsippany, NJ), Patrick; James E. (Belle Mead, NJ), Cayen; Mitchell (Bedminster, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:10/050,396
Patent Claims: 1. A method of treating a corticosteroid-responsive disease of the upper or lower airway passages or lungs, which comprises administering to the surfaces of said passages or lungs by inhalation from a dry powder inhaler of aerosolized particles of a medicament comprising daily doses about 25 to about 1000 .mu.g of mometasone furoate.

2. The method of claim 1, wherein the medicament is administered by nasal inhalation.

3. The method of claim 1, wherein the medicament is administered by oral inhalation.

4. The method of claim 1, wherein the medicament comprises particles of mometasone furoate and particles of an excipient.

5. The method of claim 1, wherein the medicament comprises particles of mometasone furoate and particles of lactose.

6. The method of claim 1, wherein the disease is at least one member selected from asthma, allergic rhinitis, non-allergic rhinitis and a non-malignant proliferative or inflammatory disease.

7. The method of claim 1, wherein the disease is at least one member selected from asthma, chronic obstructive pulmonary disease, granulomatous diseases, idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and bronchopulmonary dysplasia.

8. The method of claim 1, wherein the disease comprises rhinitis.

9. The method of claim 1, wherein the disease comprises asthma.

10. The method of claim 1, wherein the disease comprises chronic obstructive pulmonary disease.

11. The method of claim 1, wherein the mometasone furoate is administered together with a bronchodilator.

12. A method of treating asthma, comprising administering to the surfaces of airway passages or lungs of patients by inhalation from a dry powder inhaler of aerosolized particles of a medicament comprising daily doses about 25 to about 1000 .mu.g of mometasone furoate, effective for treating said asthma.

13. The method of claim 12, wherein the mometasone furoate is administered together with a bronchodilator.

14. A method of treating chronic obstructive pulmonary disease, comprising administering to the surfaces of airway passages or lungs of patients by inhalation from a dry powder inhaler of aerosolized particles of a medicament comprising daily doses about 25 to about 1000 .mu.g of mometasone furoate, effective for treating said disease.

15. The method of claim 14, wherein the mometasone furoate is administered together with a bronchodilator.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc